VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a report released on Monday. The firm set a “sell” rating on the stock.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $2.50 price objective on shares of VolitionRx in a research report on Thursday, May 16th.

VolitionRx Price Performance

Shares of VNRX stock opened at $0.65 on Monday. The stock’s fifty day simple moving average is $0.69 and its 200 day simple moving average is $0.83. The firm has a market cap of $53.59 million, a price-to-earnings ratio of -1.40 and a beta of 1.14. VolitionRx has a one year low of $0.55 and a one year high of $1.55.

VolitionRx (NYSE:VNRX) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01. The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.27 million. On average, research analysts anticipate that VolitionRx will post -0.31 earnings per share for the current year.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC purchased a new position in VolitionRx Limited (NYSE:VNRX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned approximately 0.19% of VolitionRx at the end of the most recent reporting period. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.